Your browser is no longer supported. Please, upgrade your browser.
ACHN Achillion Pharmaceuticals, Inc. daily Stock Chart
Achillion Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.47 Insider Own15.78% Shs Outstand140.09M Perf Week-8.26%
Market Cap575.77M Forward P/E- EPS next Y-0.09 Insider Trans0.00% Shs Float136.57M Perf Month-2.84%
Income-63.80M PEG- EPS next Q-0.16 Inst Own89.70% Short Float7.36% Perf Quarter12.91%
Sales15.00M P/S38.38 EPS this Y-42.20% Inst Trans0.01% Short Ratio6.48 Perf Half Y1.23%
Book/sh2.80 P/B1.47 EPS next Y85.90% ROA-15.40% Target Price6.75 Perf Year-53.14%
Cash/sh2.71 P/C1.52 EPS next 5Y17.58% ROE-15.90% 52W Range3.15 - 9.49 Perf YTD-0.48%
Dividend- P/FCF- EPS past 5Y8.10% ROI-16.20% 52W High-56.71% Beta1.98
Dividend %- Quick Ratio36.10 Sales past 5Y127.30% Gross Margin- 52W Low30.48% ATR0.21
Employees81 Current Ratio36.10 Sales Q/Q- Oper. Margin- RSI (14)38.93 Volatility4.08% 4.68%
OptionableYes Debt/Eq0.00 EPS Q/Q-11.50% Profit Margin- Rel Volume1.08 Prev Close4.32
ShortableYes LT Debt/Eq0.00 EarningsAug 03 AMC Payout- Avg Volume1.55M Price4.11
Recom1.80 SMA20-9.44% SMA50-5.95% SMA200-8.39% Volume1,681,353 Change-4.86%
May-18-17Upgrade Leerink Partners Mkt Perform → Outperform
Feb-02-17Initiated Ladenburg Thalmann Buy $10
Nov-04-16Upgrade Chardan Capital Markets Sell → Neutral $5
Sep-23-16Reiterated Chardan Capital Markets Sell $4 → $5
Sep-23-16Initiated Wedbush Outperform $13
Sep-15-16Initiated FBR & Co. Outperform $16
Jul-14-16Initiated Chardan Capital Markets Sell $4
Jul-07-16Upgrade JMP Securities Mkt Perform → Mkt Outperform
Feb-26-16Upgrade Robert W. Baird Neutral → Outperform $10
Feb-25-16Reiterated Maxim Group Buy $11 → $8
Sep-09-15Initiated Jefferies Hold
Aug-13-15Reiterated Maxim Group Buy $19 → $11
May-20-15Reiterated Leerink Partners Outperform $25 → $16
May-20-15Downgrade JMP Securities Mkt Outperform → Mkt Perform
Mar-10-15Reiterated Maxim Group Buy $22 → $19
Mar-04-15Initiated Barclays Underweight $8
Dec-23-14Downgrade Robert W. Baird Outperform → Neutral $12 → $16
Aug-15-14Reiterated Maxim Group Buy
Aug-15-14Initiated FBR Capital Outperform $12
Jun-16-14Reiterated Maxim Group Buy $6 → $22
Jul-20-17 08:38AM  Is the Options Market Predicting a Spike in Achillion Pharmaceuticals (ACHN) Stock? Zacks
Jul-19-17 09:09AM  Achillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ACHN-US : July 19, 2017 Capital Cube
Jul-10-17 04:05PM  Achillion Pharmaceutials Announces Key Promotion and Discovery Organization Change GlobeNewswire
Jun-22-17 08:00AM  Achillion Pharmaceuticals Financials, Price Targets and Pipeline Review Accesswire
Jun-15-17 04:05PM  Achillion to Present at the 2017 JMP Securities Life Sciences Conference GlobeNewswire
Jun-09-17 04:17AM  Achillion (ACHN) Up 31.1% Since Earnings Report: Can It Continue? Zacks
Jun-05-17 04:51PM  Achillion to Present at the Jefferies 2017 Global Healthcare Conference GlobeNewswire
08:00AM  Today's Research Reports on Stocks to Watch: Achillion Pharmaceuticals and TG Therapeutics Accesswire
May-19-17 08:00AM  Today's Research Reports on Biotech Stocks to Watch: Achillion Pharmaceuticals and CytRx Accesswire
May-18-17 02:26PM  Why Achillion Pharmaceuticals Stock Is Jumping 15% Today Motley Fool +16.67%
12:10PM  Achillion: It Can't Get Any WorseOr Can It?
May-11-17 06:04PM  Achillion Pharmaceuticals, Inc. Value Analysis (NASDAQ:ACHN) : May 11, 2017 Capital Cube
May-10-17 08:15AM  Achillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ACHN-US : May 10, 2017 Capital Cube
May-08-17 02:01PM  Achillion (ACHN) Reports Wider-than-Expected Loss in Q1 Zacks
May-04-17 06:24AM  Achillion reports 1Q loss Associated Press
06:05AM  Achillion Reports First Quarter 2017 Financial Results and Provides Update on Clinical Programs GlobeNewswire
May-02-17 06:05AM  Achillion to Present at the Deutsche Bank 42nd Annual Health Care Conference GlobeNewswire
Apr-25-17 03:18PM  ETFs with exposure to Achillion Pharmaceuticals, Inc. : April 25, 2017 Capital Cube +8.41%
08:36AM  Why Achillion Pharmaceuticals Stock Sank on Monday Motley Fool
07:30AM  Today's Research Reports on Stocks to Watch: Achillion Pharmaceuticals and XOMA Accesswire
Apr-24-17 04:59PM  Why Achillion Pharmaceuticals, Noble Corp., and RLJ Lodging Trust Slumped Today Motley Fool -11.81%
Apr-22-17 03:00AM  Achillion Announces Additional Phase 2 Results Including 100% SVR24 for Genotype 1 HCV After 6-Weeks of Once Daily JNJ-4178 GlobeNewswire
Apr-20-17 06:22PM  If You Don't Buy These 5 Stocks Before Their Looming Breakout, It's Your Loss
Apr-06-17 06:05AM  Achillion Announces Initiation of Patient Dosing in Phase 2 Study of ACH-4471 for Paroxysmal Nocturnal Hemoglobinuria GlobeNewswire
Mar-31-17 09:30AM  Today's Research Reports on Stocks to Watch: Achillion Pharmaceuticals and Corbus Pharmaceuticals Accesswire
Mar-30-17 08:12AM  Achillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ACHN-US : March 30, 2017 Capital Cube
Mar-28-17 08:45AM  Why Is Achillion (ACHN) Down 11.3% Since the Last Earnings Report? Zacks
Mar-21-17 04:05PM  USPTO Grants Composition of Matter Patent to Achillion for Small Molecule Complement Alternative Pathway Factor D Inhibitors GlobeNewswire
Mar-07-17 01:53PM  Achillion Pharmaceuticals, Inc. :ACHN-US: Earnings Analysis: Q4, 2016 By the Numbers : March 7, 2017 Capital Cube
09:32AM  Catalyst Pharma (CPRX): What???s in Store in Q4 Earnings?
Mar-06-17 08:46AM  Celldex Therapeutics (CLDX) Q4 Earnings: What's in Store? Zacks
Mar-02-17 01:21PM  These 5 Stocks Under $10 Could Explode Up Soon
Mar-01-17 05:42PM  Aerie Pharmaceuticals (AERI) Q4 Earnings: What to Expect?
Feb-28-17 06:05AM  Achillion Pharmaceuticals to Support a Natural History Study of C3 Glomerulopathy, a Rare Renal Disorder, Conducted by Experts at Imperial College London GlobeNewswire
Feb-27-17 08:23AM  Achillion (ACHN) Reports Narrower-Than-Expected Q4 Loss Zacks +6.74%
Feb-24-17 09:38AM  Biotech Movers: Cempra Flys High On Phase Three Results -8.96%
07:42AM  Achillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ACHN-US : February 24, 2017
Feb-23-17 05:31PM  Achillion reports 4Q loss
04:38PM  ACHILLION PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
04:31PM  ACHILLION PHARMACEUTICALS INC Files SEC form 10-K, Annual Report
04:05PM  Achillion Reports 2016 Fourth Quarter and Year-End Financial Results GlobeNewswire
Feb-22-17 09:30AM  Biotech's Rally Continues to Build in 2017: Today's Reports on Achillion Pharmaceuticals and Pulmatrix Accesswire
Feb-13-17 06:05AM  Achillion to Present at the Leerink Partners 6th Annual Global Healthcare Conference GlobeNewswire
Feb-03-17 07:30AM  Achillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ACHN-US : February 3, 2017
Feb-02-17 09:27AM  Premarket Biotech Movers: Cytokinetics, Achillion, Qiagen
07:12AM  Coverage initiated on Achillion Pharma by Ladenburg Thalmann
Jan-25-17 08:15AM  Blog Coverage FDA Approved Orphan Drug Designation for TG Therapeutics' Combination of TG-1101 and TG-1202 Accesswire
Jan-23-17 10:15AM  J&J Arm Buys Megadyne, Boosts Electrosurgical Tools Portfolio
Jan-11-17 10:18AM  Achillion Pharmaceuticals, Inc. Value Analysis (NASDAQ:ACHN) : January 11, 2017 -6.26%
Jan-10-17 07:20AM  Achillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ACHN-US : January 10, 2017
Jan-09-17 10:05AM  Where are the opportunities for investors in health care?
Dec-29-16 08:05AM  Achillion Receives $15M from J&J for HCV Study Enrolment
Dec-28-16 08:16AM  ACHILLION PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements an
06:05AM  Achillion Announces Clinical Milestone for the Advancement of JNJ-4178 in Phase 2B Development for Chronic HCV GlobeNewswire
Dec-08-16 01:04PM  These 5 Stocks Under $10 Could Make You a Lot of Money
Dec-05-16 04:05PM  Data Presented at American Society of Hematology Meeting Demonstrate Potential Advantages of Factor D Inhibition for the Treatment of Complement Alternative Pathway-Mediated Diseases GlobeNewswire
12:48PM  The Main Reason Achillion Pharmaceuticals, Inc. Collapsed 34% in November at Motley Fool
Dec-01-16 01:23PM  Has The Smart Money Found A Winner in Infoblox Inc (BLOX)? at Insider Monkey
10:20AM  Achillion, J&J to Initiate Phase IIb Study on HCV Combo
Nov-30-16 06:05AM  Achillion Announces Initiation of Patient Dosing by Janssen in a Global, Short Treatment-Duration Phase 2b Study of JNJ-4178 in Chronic HCV GlobeNewswire
Nov-26-16 06:15PM  This Metric Says It May Be Time to Buy Achillion Pharmaceuticals, Inc. (ACHN) at Insider Monkey
Nov-21-16 08:36AM  Achillion Pharmaceuticals (ACHN) is Oversold: Can It Recover?
Nov-17-16 08:15AM  Blog Coverage GTx Inc. Enobosarm Achieves Stage 1 Milestone Accesswire
Nov-14-16 09:41AM  Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) to Ring The Nasdaq Stock Market Closing Bell GlobeNewswire
Nov-07-16 08:29AM  Achillion (ACHN) Reports Narrower-Than-Expected Q3 Loss
Nov-05-16 10:05AM  8 Companies That Destroyed Shareholders This Week at 24/7 Wall St.
Nov-03-16 08:25PM  Why Achillion Pharmaceuticals Is Crashing 36% Today at Motley Fool -28.48%
05:03PM  Health Sector Down As Report of Industry Price Collusion Surfaces
04:23PM  ACHILLION PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
04:22PM  ACHILLION PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
12:50PM  5 Cult Stocks Getting Absolutely Destroyed After Earnings at 24/7 Wall St.
12:29PM  Why Achillion Has Plunged 30% at
10:31AM  The Great 'ASH16' Abstract Drop Mostly Causes Drug Stocks to Do Same
09:14AM  Achillion reports 3Q loss
09:01AM  Achillion Announces Upcoming Presentations of Novel Research Into Complement Biology at the 58th Annual Meeting of the American Society of Hematology GlobeNewswire
09:00AM  Achillion Reports Third Quarter 2016 Financial Results And Provides Update On Clinical Programs GlobeNewswire
Nov-02-16 06:05AM  Achillion to Present at the Credit Suisse 25th Annual Healthcare Conference GlobeNewswire
Oct-21-16 10:29AM  Baxter International (BAX) Q3 Earnings: Beat in the Cards?
Oct-20-16 07:51AM  What's in Store for Boston Scientific's (BSX) Q3 Earnings?
Oct-17-16 09:19AM  St. Jude Medical (STJ) Q3 Earnings: What's in the Cards?
Oct-13-16 09:46AM  Will These 5 Drug Stocks Be Big Winners This Earnings Season?
Oct-08-16 09:22AM  Five Cheap Healthcare Stocks Poised to Explode at Insider Monkey
Oct-06-16 08:35AM  Intellia (NTLA) Worth Watching: Stock Rises 5.2% in Session
Oct-05-16 09:30AM  The Zacks Analyst Blog Highlights: VIVUS, Geron, Achillion Pharmaceuticals, Anika Therapeutics and ANI Pharmaceuticals
08:15AM  Ocera Therapeutics (OCRX) Jumps: Stock Moves Up 8.5%
Oct-04-16 01:53PM  Biotech Mergers Run the Show: 5 Small-Cap Stocks for Q4
10:05AM  Roche Alecensa Wins Second Breakthrough Status in the U.S.
09:12AM  Jazz Initiates Rolling NDA for Leukemia Candidate Vyxeos
Oct-01-16 12:13PM  Hey Gilead, It's Time to Start Looking Over Your Shoulder in Hepatitis C at Motley Fool
Sep-27-16 10:39AM  Achillion Pharmaceuticals, Inc. Value Analysis (NASDAQ:ACHN) : September 27, 2016
Sep-26-16 09:00AM  Achillion, J&J HCV Triple Combination Drug Data Presented
08:12AM  Achillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ACHN-US : September 26, 2016
Sep-25-16 10:45AM  6 Biotech and Biohealth Analyst Picks for 50% to 150% Upside at 24/7 Wall St.
Sep-23-16 11:50AM  Achillion Announces 100% SVR12 in the 6-Week and 8-Week Cohorts in Janssens Phase 2 Trial Evaluating the Triple Combination Treatment Regimen Including Odalasvir, AL-335, and Simeprevir for Genotype 1 Treatment-Naïve HCV GlobeNewswire
Sep-13-16 07:42AM  Biotech Movers: Lantheus Holdings Inc (LNTH) and Achillion Pharmaceuticals, Inc. (ACHN) at Insider Monkey
Sep-12-16 08:43AM  Achillion, J&J's HCV Combo Drug Positive in Phase IIa Trial
Sep-09-16 06:15AM  Achillion Announces 100% SVR Reported in Janssens Phase 2a Trial Evaluating Triple Combination of Odalasvir, AL-335, and Simeprevir for Genotype 1 Treatment-Naive HCV GlobeNewswire -6.07%
Sep-06-16 06:05AM  Achillion Presents Novel Research on Factor D Inhibition at the XXVIth International Complement Workshop GlobeNewswire
Sep-02-16 07:40AM  8 Major FDA Decisions and Trial Results to Watch for in September at 24/7 Wall St.
Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for infectious diseases and immune system disorders in the United States and internationally. Its drug candidates for treating chronic hepatitis C virus (HCV) infection comprise Odalasvir, a NS5A inhibitor, which has completed Phase IIa clinical trials; ACH-3422, a NS5B nucleotide polymerase inhibitor; and Sovaprevir, a NS3 protease inhibitor that has completed Phase II clinical trial. The company is also developing ACH-4471, a complement factor D inhibitor, which is in Phase I clinical trial to treat patients with paroxysmal nocturnal hemoglobinuria and C3G, a disease resulting from alternative pathway over-activation; and other factor D inhibitors. It has a license and development agreement with Ora, Inc. for the development and commercialization of ACH-702, a drug candidate that is delivered topically or locally; and collaboration arrangement with Janssen Pharmaceuticals Inc. to develop and commercialize antiviral drug candidates for treating HCV infection. The company was founded in 1998 and is headquartered in New Haven, Connecticut.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FISHERMAN JASON SDirectorDec 22Buy3.9610,00039,60050,000Dec 23 10:09 AM
Fenton Mary KayChief Financial OfficerDec 05Buy4.112,50010,2752,500Dec 05 05:16 PM
Truitt JosephChief Commercial OfficerDec 02Buy4.063,50014,2103,500Dec 05 05:18 PM
Deshpande MilindChief Executive OfficerDec 02Buy4.062,50010,1502,500Dec 05 05:16 PM
MANNING MARTHA EEVP, General CounselDec 02Buy4.092,50010,2252,500Dec 05 05:17 PM
Barrish Joel CChief Scientific OfficerDec 02Buy4.062,50010,1502,500Dec 05 05:15 PM